<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503474</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS244784</org_study_id>
    <nct_id>NCT03503474</nct_id>
  </id_info>
  <brief_title>COMBACTE-CDI Understanding the Burden of C. Difficile Infection</brief_title>
  <acronym>COMBACTE-CDI</acronym>
  <official_title>Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections (COMBACTE-CDI, Understanding the Burden of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovative Medicines Innitiative 2</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Centre Utrecht, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Centre, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National laboratory for Health, Environment and Food, Slovenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitatsklinikum Koln, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Antwerp, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Infectious Diseases 'Lazzaro Sapllanzani', Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eberhard Karls University of Tubingen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioMÃ©rieux</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Da Volterra</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leeds</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clostridium difficile infection (CDI) is the most common cause of antibiotic associated
      diarrhoea in the western world. The infection causes significant diarrhoea, which in some
      cases can be serious and lead to secondary complications and even death. The infection is
      particularly an issue in elderly, frail patient, who are often already burdened with several
      other medical issues. Recent work has demonstrated that numerous cases are missed, either due
      to inadequate diagnostic tests or lack of clinical suspicion.

      The public-private partnership in COMBACTE-CDI will quantify the burden of CDI via a large,
      complex, multi-centre, multi-country study, and describe current management practices. An
      increased understanding of the CDI burden across Europe and better understanding of
      transmission of the organism will provide a basis for the further development of public
      health interventions and practices.

      Based on a previous successful study model (EUCLID), hospitals/laboratories of interest which
      carry out diagnostic testing of samples from both in-patients and community patients
      (including Long-Term Care Facilities patients) will be approached for inclusion in the study.
      Samples sent to the sites on the selected study date (regardless of test requested) will be
      tested at a central laboratory for CDI to look for missed cases of CDI. A follow up
      case/control study will collect data on outcomes and risk factors. Data will be used to
      construct transmission models and cost effective-ness models. Ultimately, a best practice
      model for CDI management will be developed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of cases of CDI</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3240</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>CDI cases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CDI negative controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>There is no intervention, this is observational only</description>
    <arm_group_label>CDI cases</arm_group_label>
    <arm_group_label>CDI negative controls</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      residual diagnostic faecal samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Anyone who has a diarrhoeal faecal sample submitted to the laboratories in the study for
        testing on the day of interest, regardless of test requested
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anyone who has a diarrhoeal faecal sample submitted to the laboratories in the study
             for testing on the day of interest, regardless of test requested

        Exclusion Criteria:

          -  Any repeat samples
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wilcox, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Leeds</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Wilcox, MD</last_name>
    <phone>+441133926818</phone>
    <email>mark.wilcox@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerrie Davies, MSc</last_name>
    <phone>+441133928664</phone>
    <email>kerrie.davies@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Wilcox, MD</last_name>
      <phone>+44113 3926818</phone>
      <email>mark.wilcox@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leeds</investigator_affiliation>
    <investigator_full_name>Professor Mark Wilcox</investigator_full_name>
    <investigator_title>Brotherton Chair of Microbiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

